# Treatment of Melanoma CNS Metastases 

Sekwon Jang and Michael B. Atkins


#### Abstract

The discovery of the BRAFV600 mutation and the development of targeted therapies directed against this mutation as well as effective immunotherapies with durable benefits have revolutionized the treatment of patients with melanoma. Nonetheless, the frequent occurrence of brain metastases in patients with advanced melanoma represents a significant obstacle to long-term, high quality survival. The application of stereotactic radiation therapy has provided an opportunity to control brain metastases in the majority of patients with metastatic melanoma reducing the impact of these lesions on morbidity and mortality and enabling patients to receive and potentially benefit from these novel systemic treatments. Encouragingly, several of these novel new therapies have shown antitumor activity against CNS metastases that approach that seen against extracranial disease. As a consequence, several effective treatment options are now available for patients with melanoma brain metastases. With these tools in hand, it is anticipated that further investigation into the optimal sequence and/or combination of systemic therapies and local therapies along with multidisciplinary team practice will continue to improve the outcome of patients with this previously life-limiting disease complication.


[^0]
[^0]:    S. Jang $\cdot$ M.B. Atkins ( $\boxtimes$ )

    Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA
    e-mail: mba41@georgetown.edu# Keywords 

Melanoma brain metastases $\cdot$ Stereotactic radiosurgery $\cdot$ Braf inhibitor therapy $\cdot$ Immunotherapy

## Contents

1 Introduction ..... 264
2 Treatment ..... 265
2.1 Surgery ..... 265
2.2 Radiation Treatment ..... 266
2.3 Systemic Treatment ..... 268
2.4 Combination ..... 273
3 Conclusion ..... 274
References ..... 275

Melanoma brain metastases are common, difficult to treat, and carry a poor prognosis. Local therapies such as surgery and whole-brain radiotherapy (WBRT) have historically been the only treatment approaches for patients with melanoma brain metastases. Over the past decade, stereotactic radiosurgery (SRS) has become the cornerstone of treatment for most patients. Selection and sequencing of local therapies are controversial due to lack of prospective randomized trials addressing this question. More recently, the treatment paradigm for melanoma brain metastases has begun to incorporate systemic treatments including molecularly targeted therapies such as the BRAF inhibitors dabrafenib and vemurafenib and immunotherapy with the anti-CTLA4 antibody ipilimumab. Given the expanding number of treatment options, multidisciplinary discussion is required to establish a treatment plan which balances multiple factors including reduction in symptomatic central nervous system (CNS) disease progression and the risk of neurologic death against the risk of treatment-related toxicity and competing issues related to the management of systemic disease. Further research is required to optimize the coordination of all the available therapies, both local and systemic, to improve the patient's quality of life and survival.

## 1 Introduction

Melanoma has high propensity to metastasize to the brain and is the third most common cause of brain metastases in the USA after lung and breast cancers [35]. Five-year cumulative incidence of brain metastases was $7 \%$ for patients with all stages of melanoma [63]. Approximately $20 \%$ of patients have brain metastases at first diagnosis of distant metastatic melanoma [8]. Additionally up to $45 \%$ of patients with metastatic melanoma develop clinically documented brain metastases during their lifetime [13], and the prevalence of brain metastasis is $50-75 \%$ in autopsy series $[14,53]$.Clinicopathologic characteristics associated with the increased risk of brain metastases among patients with melanoma mirror those factors associated with metastasis and poor survival. They include male gender, melanomas arising on mucosal surfaces or on the skin of the trunk or head and neck, thick or ulcerated primary lesions, and acral lentiginous or nodular histology [61]. Also, melanoma involvement of more than three regional lymph nodes either at diagnosis or relapse was associated with the development of brain metastases [5]. Among patients with unresectable stage III or IV melanoma, elevated LDH and stage M1b or M1c were independent predictors for the risk of brain metastasis [6]. Molecular changes found in melanoma brain metastases include increased VEGF secretion, increase in phosphorylated STAT3 leading to upregulation in invasive and angiogenesis genes, and increased activity of heparanase (Chen and Davies [11]). Also, patients with melanomas containing BRAF or NRAS mutations were more likely than patients with wild-type tumors to have brain metastasis at the time they were diagnosed with distant metastatic disease [33].

Melanoma patients with brain metastases historically have had a poor prognosis with median survival of 4 months and 1-year survival rate of $10-20 \%$ [18, 61]. An improvement in median overall survival to 8 to 10 months has been reported with SRS [39, 60]. In patients with brain metastases from melanoma, good performance status and the limited number of brain metastases were associated with a more favorable prognosis [67].

# 2 Treatment 

### 2.1 Surgery

Prospective randomized studies in patients with brain metastases from largely other histologies have suggested that surgical resection followed by WBRT produced superior results to WBRT alone. For example, a randomized trial of 48 patients with a single metastasis to the brain including 3 patients with melanoma showed improvement in survival among patients who received treatment with surgical resection plus radiotherapy compared to patients treated with radiotherapy alone. Also, patients who were treated with surgery plus radiotherapy had fewer recurrences of cancer in the brain and had a better quality of life [52]. Another trial also demonstrated surgery plus radiotherapy produced superior overall and functionally independent survival compared to radiotherapy alone in patients with single brain metastasis especially those with stable extracranial disease (median survival, 12 months vs. 7 months) [70]. A systematic review also concluded that surgical resection followed by WBRT is an effective treatment for patients with a single, surgically accessible brain metastasis who have controlled extra-cranial disease and are in good general condition [21]. While this approach is an established practice for many cancers, the relevance of these findings to patients with melanoma withsolitary brain metastases is uncertain as melanoma is typically less sensitive to standard low-dose fractionated WBRT approach.

Of note, a retrospective study from Australia confined to patients with melanoma showed improvement in median survival among patients with melanoma brain metastasis treated with surgery ( 8.9 months) or surgery and postoperative radiotherapy ( 9.7 months) compared to radiotherapy alone ( 3.4 months) or supportive care alone ( 2.1 months) [18]. Although the group treated with surgery likely had a significantly better pretreatment prognosis than those treated with WBRT alone or supportive care, these data are perhaps most notable for the limited benefit associated with WBRT in either the postsurgical or inoperable setting.

While surgical resection of more than one brain metastasis has been performed in cases of significant mass effect from more than one lesion, and in cases where two or more lesions are accessible through the same craniotomy approach, no robust comparative data exist to evaluate the role of surgical resection for multiple brain metastases in any cancer let alone for melanoma [36]. Retrospective review of 56 patients who underwent resection for multiple brain metastases reported improved survival in patients who had all of their brain metastases resected compared to patients who had resection of only some of the lesions (median survival, 14 months vs. 6 months) [7]. The survival was comparable to a matched control group of patients who underwent resection for a single brain metastasis. Although multiple large, symptomatic metastases can be treated with surgical resection in selected patients with favorable prognosis, SRS and/or WBRT is far more commonly employed in patients with multiple brain metastases.

# 2.2 Radiation Treatment 

WBRT has played a central role in brain metastasis treatment and continues to be central to therapy for many tumor types with radioresponsive biology. However, melanoma cells have low responsiveness to radiation in vitro corresponding to the low efficacy of WBRT [17]. As mentioned above, patients with melanoma that had metastasized to brain who underwent WBRT alone had a median survival of only 3.4 months compared to 2.1 months for patients who received supportive care alone [18]. Given this limited benefit, WBRT in patients with melanoma has been increasingly confined to patients for whom surgery and SRS are not feasible such as those with symptomatic diffuse or leptomeningeal disease as well as inoperable large-volume brain metastatic disease.

Although prior data from patients largely with other cancers suggested a benefit for adjuvant WBRT following surgical resection [51], more recent data have called this benefit into question. A prospective randomized study conducted by the European Organisation for Research and Treatment of Cancer (EORTC) evaluated the role of adjuvant WBRT after surgery or radiosurgery in 359 patients ( 18 with melanoma) with one to three brain metastases and demonstrated no improvement in the duration of functional independence or overall survival despite improvement inlocal and distant brain control [38]. Also, adjuvant WBRT had negative impact on health-related quality of life (global health status at 9 months, physical functioning at 8 weeks, cognitive functioning at 12 months, and fatigue at 8 weeks) compared to observation [65].

In the absence of melanoma-specific data, it is difficult to estimate the benefit of WBRT as an adjuvant therapy following surgery or radiosurgery. The benefit would be expected to be greatest for patients undergoing resection or radiosurgery to large metastases (i.e., $>4 \mathrm{~cm}$ ) where the radiosurgery dose to tumor or resection cavity would need to be relatively low [56].

In contrast to the limited benefit and role of WBRT, SRS has emerged as a vital alternative local therapy for patients with melanoma brain metastases. This approach utilizes multiple convergent radiation beams to deliver a high dose of focused radiation to one or more tumor masses with rapid dose falloff beyond the tumor margin. Multiple single-institution retrospective analyses reported 1-year local control rates of $50-75 \%$ in patients who underwent SRS for melanoma brain metastases [9, 39]. Studies identified tumor volume as an independent predictor of local tumor control [9, 42] and survival [73]. Also, patients with controlled extracranial melanoma metastases had better survival [39, 73].

Although there is substantial experience with SRS in patients with melanoma brain metastases, there is no prospective randomized melanoma-specific trial addressing the benefit of SRS to patient survival. The Radiation Therapy Oncology Group (RTOG) conducted a trial including multiple histologies (13 of 333 patients with melanoma) with up to three brain metastases and randomized patients to WBRT + SRS or WBRT alone [3]. The addition of SRS improved survival for patients with single unresectable brain metastasis but not for patients with multiple metastases. Patients who had WBRT + SRS were more likely to maintain a stable or improved performance status at 3 and 6 months compared to patients who had WBRT alone. Based on this, the authors concluded that SRS should be a standard treatment for patients with a single unresectable brain metastasis and considered for patients with two or three brain metastases.

Current radiosurgery delivery systems are capable of treating multiple (up to 10) metastases in a single session. However, the optimal treatment of patients with multiple brain metastases ( 4 or more) remains controversial, and only a few retrospective studies have included patients with 4 or more metastatic lesions. One study showed that patients with single brain metastasis had better survival compared with patients with multiple brain metastases after SRS (Radbill et al. [55]). Another study also showed that the number of brain metastases was an independent predictor of survival; however, long-term survival was observed in patients with up to 8 brain metastases, no prior WBRT, and good functional status [39]. Although these data once again come largely from patients with other cancer types, these data suggest that SRS is a valuable option for patients with controlled systemic disease even if they have multiple brain metastases.

The effectiveness of SRS compared to conventional surgery remains uncertain. In the absence of randomized trial, surgery is preferred if a single metastatic lesion is causing neurologic symptoms and is easily accessible. Large posterior fossatumors or those with the large amounts of surrounding edema causing significant effacement of the fourth ventricle or cerebral aqueduct should be resected to prevent the development of obstructive hydrocephalus. SRS is preferred for smaller lesions and those in eloquent or relatively inaccessible areas of the brain.

There has been a great interest to add SRS following surgical resection of a brain metastasis. Multiple retrospective studies have demonstrated that a postoperative SRS boost in lieu of WBRT is associated with high local control rate with acceptable toxicity [33, 66]. While further studies evaluating SRS versus WBRT, or fractionated stereotactic radiotherapy, may clarify the optimal radiation modality in this setting for patients with radiosensitive malignancies, given the relative radioresistance of melanoma, adjuvant SRS is likely to be the preferred option for patients with melanoma brain metastases.

Radiation necrosis is the most common complication following SRS. It is diagnosed from radiologic evidence of increased peritumoral edema and rim enhancement at the radiosurgical site. In one series, radiation necrosis occurred in $24 \%$ of treated lesions, being symptomatic in $10 \%$ and asymptomatic in $14 \%$ [46]. Predictive factors for radiation necrosis included tumor size, location, and volume of normal brain receiving 10,12 , and 16 Gy (V10, V12, and V16) especially when located in or near eloquent areas. The standard treatment for symptomatic radiation necrosis consists of corticosteroids. For patients with melanoma, steroid treatment may adversely affect the efficacy of systemic immunotherapies such as interleukin-2 or ipilimumab. In such cases, aggressive management including surgical resection of the necrotic area may be considered. Administration of low-dose bevacizumab has also been reported to be effective in the treatment of radiation-induced necrosis [2] and could be considered particularly in situations where corticosteroids are contraindicated and surgical resection is not feasible. Upfront surgical resection or fractionated stereotactic radiotherapy may be considered for metastases that would be associated with excessive risk of radiation necrosis following SRS.

# 2.3 Systemic Treatment 

### 2.3.1 Chemotherapy

Cytotoxic chemotherapy has limited efficacy for patients with metastatic melanoma to the brain. Temozolomide and fotemustine can penetrate the blood-brain barrier and have produced the highest response rates among conventional chemotherapies. Temozolomide was evaluated in a phase II study in patients with melanoma brain metastases who did not require immediate radiotherapy [1]. Of 151 patients enrolled, 117 who had no prior systemic chemotherapy received temozolomide $200 \mathrm{mg} \mathrm{m}^{2}$ day for 5 days every 28 days, whereas 34 who had prior chemotherapy received $150 \mathrm{mg} \mathrm{m}^{2}$ day for 5 days every 28 days. Response rates were $7 \%$ for previously untreated patients and $3 \%$ for previously treated patients. Median overall survival was poor- 3.5 and 2.2 months for previously untreated patients and for previously treated patients, respectively. Another phase II study evaluatedthe combination of temozolomide and thalidomide and found modest response rate of $12 \%$ with increased toxicity such as intracranial hemorrhage, pulmonary embolism, and deep vein thrombosis [31]. Clinical activity of fotemustine was initially suggested in a phase II trial showing a response rate of $24 \%$ in patients with melanoma brain metastases [32]. However, in a phase III trial of fotemustine compared with dacarbazine, tumor responses were observed rarely in brain ( $5.9 \%$ with fotemustine vs. $0 \%$ with dacarbazine) among patients with brain metastases at baseline.

# 2.3.2 Immunotherapy 

## Interleukin-2

Prior to 2011, high-dose interleukin-2 (IL-2) was the only approved immunotherapy in the USA for patients with advanced melanoma and has been used for patients without brain metastases with objective responses observed in 15-20 \% and durable complete responses in 5-7 \% of patients. Data are limited on the safety and efficacy of high-dose IL-2 in patients with untreated brain metastases. In a retrospective review from the US National Cancer Institute, IL-2 yielded objective response rate of $18 \%$ in patients with previously irradiated brain metastases but only $6 \%$ in patients with untreated brain metastases [23]. There were no significant differences in toxicity profiles. Given the substantial capillary leak syndrome and the associated risk for peritumoral edema, seen with high-dose IL-2 therapy, treatment of patients with large CNS metastases, even if recently irradiated, may be associated with significant CNS toxicity. Further, the CNS is a frequent site of isolated disease relapse for patients with ongoing systemic response to IL-2-based immunotherapy, suggesting that the efficacy of this treatment in controlling disease in the brain is even more limited than its modest ability to treat systemic metastatic disease [30, 47]. Finally, IL-2 therapy has been shown to be ineffective in patients taking steroids [45]. Consequently, the use of HD IL-2 in patients with extensive CNS melanoma metastases is to be discouraged.

## Adoptive T-cell Therapy

Adoptive T-cell therapy is a complex treatment that is performed in few centers worldwide. It uses autologous antitumor lymphocytes plus interleukin-2 following a lymphodepleting preparative regimen used to eliminate the immunosuppressive factors within the tumor microenvironment. This approach has a high antitumor activity in patients with systemic metastases from melanoma [59]. A retrospective analysis from US National Cancer Institute Surgery Branch reported that this approach also has activity against CNS metastases [29]. Patients were eligible for treatment if they had asymptomatic oligometastases each less than 10 mm in size and unassociated with mass effect or edema. A complete response was reported in 7 of 17 evaluable patients ( $41 \%$ ), and 6 of these patients achieved an overall partial response. One patient developed a tumor-associated subarachnoid hemorrhage during the thrombocytopenic phase of therapy. This impressive result should beinterpreted with caution given the small number of highly selected patients analyzed.

# Ipilimumab 

Ipilimumab is a fully human monoclonal antibody (IgG1) which inhibits the function of cytotoxic T-cell-associated antigen 4 (CTLA4) and enhances an immune response against melanoma cells. Ipilimumab $3 \mathrm{mg} / \mathrm{kg}$ intravenously every 3 weeks for up to 4 cycles was approved in 2011 for patients with metastatic melanoma based on a survival advantage over a melanoma vaccine [27]. Also, ipilimumab in combination with DTIC improved survival compared with DTIC alone [57]. Patients with active or untreated brain metastases were excluded from these trials. However, ipilimumab was observed to induce immune effector cell infiltration and tumor necrosis in brain metastases, and cases of regression or stabilization of previously progressing brain metastases in ipilimumab-treated patients have been reported $[28,62]$.

Activity of ipilimumab against brain metastases was specifically addressed by a phase II study including two cohorts of patients [44]. Patients in cohort A $(n=51)$ had one or more untreated brain lesions who were neurologically asymptomatic and were not receiving corticosteroid treatment at study entry. Those in cohort B $(n=21)$ were symptomatic and on a stable dose of corticosteroids. Patients were treated with ipilimumab, $10 \mathrm{mg} / \mathrm{kg}$ intravenously every 3 weeks for 4 cycles followed by same dose every 12 weeks for those who were clinically stable. Intracranial disease control (objective response or stable disease) rate was $24 \%$ in cohort A and $10 \%$ in cohort B using modified WHO criteria and $25 \%$ in cohort A and $10 \%$ in cohort B using immune-related response criteria. Extracranial disease control was mostly concordant with the intracranial disease control. The 24 -month overall survival was $26 \%$ in cohort A and $10 \%$ in cohort B. The lower antitumor activity and worse survival in cohort B could be attributable to their less favorable prognostic characteristics as well as the inhibition of the immunostimulatory effects of CTLA4 checkpoint blockade by concomitant corticosteroid blockade. There were no unexpected toxicities, but it should be noted that one patient had a grade 4 intratumoral hemorrhage attributed to disease progression. Overall, ipilimumab has activity in melanoma brain metastases particularly when patients are asymptomatic and not receiving corticosteroids. Further study is required to determine the optimal dose ( $3 \mathrm{mg} / \mathrm{kg}$ vs. $10 \mathrm{mg} / \mathrm{kg}$ ) and schedule ( 4 doses only vs. 4 doses plus every 12 weeks) of ipilimumab in this as well as other treatment settings.

## Programmed Death 1 Inhibitors

Programmed death (PD) 1 is an inhibitory co-receptor on antigen-activated T cells. Inhibiting the PD-1 receptor with a blocking antibody enhances T-cell responses and antitumor activity. Early clinical trials investigating antibodies to PD-1 or PD-L1 in patients with melanoma have shown response rates ranging from 25 to $50 \%[24,69]$. In addition, a study evaluating the concurrent administration of the combination of ipilimumab and the PD1 antibody nivolumab produced rapid and deep tumor responses in patients with metastatic melanoma and an overall responserate of $53 \%$ in a small number of patients [72]. The promising results seen with various anti-PD1 and PD-L1 antibodies either alone or in combination with ipilimumab have led to multiple randomized clinical trials of comparing anti-PD-1 antibodies alone or in combination with ipilimumab to standard of care in patients with metastatic melanoma (NCT01704287, NCT01866319, NCT01844505). These new agents will likely soon be added to the therapeutic armamentarium for patients with metastatic melanoma. To date, patients with active brain metastases have been excluded from these studies; however, ongoing and future trials are anticipated to provide data on the intracranial activity of these promising agents.

# 2.3.3 Targeted Therapy 

Activating mutations in the mitogen-activated protein kinase (MAPK) pathway, which incorporates the enzymes RAS (rat sarcoma; encoded by HRAS, NRAS, and KRAS), RAF (rapidly accelerated fibrosarcoma; encoded by ARAF, BRAF, and CRAF), MEK (MAPK/ERK kinase; encoded by MAP2K1 and MAP2K2), and ERK (extracellular signal-regulated kinase; encoded by MAPK1 and MAPK3), results in constitutive signaling leading to oncogenic cell proliferation and escape from apoptosis [22]. Approximately $40-50 \%$ of melanomas harbor a mutation in the BRAF, mostly confined to a specific point mutation at nucleotide 1799 leading to a change in the V600 amino acid [12]. V600E mutation (substitution of glutamic acid for valine at position 600) is the most common BRAF mutation in melanoma occurring in $70-90 \%$ of BRAF-mutant melanomas, with the remainder of mutations largely resulting from other amino acid substitutions at this position (V600K, V600D, or V600R) [40, 71].

In 2011, vemurafenib became the first oral BRAF inhibitor approved by US FDA for the treatment of patients with unresectable or metastatic melanoma with BRAFV600E mutation. A phase 3 randomized trial comparing vemurafenib to dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAFV600E mutation demonstrated significantly increased overall survival (HR $0.37,95 \%$ confidence interval [CI], $0.26-0.55 ; P<0.001$ ) and progression-free survival (HR $0.26,95 \% \mathrm{CI}, 0.20-0.33 ; P<0.001$ ) at the first planned interim analysis conducted after a median follow-up of only 3.7 months [10]. Response rates were $48 \%$ for vemurafenib and $5 \%$ for dacarbazine. Common side effects of vemurafenib were arthralgia, rash, fatigue, alopecia, photosensitivity, nausea, and diarrhea. Cutaneous squamous cell carcinomas (the majority, keratoacanthoma type) were reported in up to $26 \%$ of patients with a significant proportion of these tumors harboring a mutation in HRAS [68]. These skin lesions were treated with local excision and did not require dose interruption or reduction of vemurafenib. As with many registration trials, patients with brain metastases were ineligible for the study unless the disease had been treated and was stable for at least three months and not requiring steroids.

A case report of dramatic response in a melanoma brain metastasis to vemurafenib [58] led to an open-label, single-arm trial in 24 patients with V600E BRAF mutation-positive melanoma and symptomatic and progressing brain metastases[15]. These patients had a very poor prognosis at enrollment, and there was no size criteria for the brain lesions. Of 19 patients with measurable intracranial disease, seven ( $37 \%$ ) achieved $>30 \%$ intracranial tumor regression, and three ( $16 \%$; $95 \%$ CI, 3.4-39.6 \%) achieved a confirmed PR. Median progression-free survival was 3.9 ( $95 \%$ CI, 3.0-5.5) months, and median overall survival was 5.3 ( $95 \%$ CI, 3.96.6) months. A larger phase II study of vemurafenib in patients with BRAF V600mutant melanoma and active brain metastases included patients with both symptomatic and asymptomatic brain metastases, as well as patients with untreated or previously treated CNS disease (NCT01378975). This trial has completed accrual, and the results are anticipated shortly.

Dabrafenib is a reversible, ATP-competitive inhibitor of mutant BRAFV600 (IC50 $0.5 \mathrm{nmol} / \mathrm{L}$ ). Dabrafenib was approved by US FDA in 2013. In a phase 3 clinical trial, 250 patients with previously untreated, stage IV or unresectable stage III BRAFV600E mutant melanoma were randomized to receive either dabrafenib ( 187 patients) or dacarbazine ( 63 patients) [26]. Patients assigned to the dacarbazine arm were permitted to crossover to dabrafenib at the time of disease progression. The primary end point of this trial was progression-free survival. Dabrafenib showed a statistically significant improvement in median progression-free survival of 5.1 months compared to 2.7 months for dacarbazine. Confirmed objective response rate by independent review committee was $50 \%$ in dabrafenib with a $3 \%$ complete response rate. These results are similar to what was observed in the vemurafenib phase III trial indicating a likely equivalent antitumor activity for these two agents. In an updated report, the median overall survival for the dabrafenib-treated group was 18.2 months compared to 15.6 months in dacarbazine group. These survival results were confounded by crossover of the majority of patients initially assigned to dacarbazine to dabrafenib (HR 0.76, $95 \%$ CI 0.481.21) [25]. The most common adverse events were cutaneous (hyperkeratosis, papillomas, palmar-plantar erythrodysaesthesia), fatigue, headache, and arthralgia, which together required dose reduction in $28 \%$ of patients. Squamous cell carcinoma or keratoacanthomas were observed in $6 \%$ of patients. Photosensitivity reactions were rarely seen with dabrafenib; however, grade 2 or 3 pyrexia was observed in 8 and $3 \%$, respectively.

The activity of dabrafenib for patients with melanoma brain metastases was first reported from the phase I expansion cohort study [16]. Among 10 patients with asymptomatic, untreated brain metastases who were treated with recommended phase II dose of 150 mg twice daily, nine patients had a reduction in the size of the brain metastases and four had a complete response in the brain. These results led to the large phase II study which enrolled 172 patients with BRAFV600E- or V600Kmutant melanoma with documented brain metastasis into one of two cohorts distinguished by whether or not they had received prior radiation therapy to brain [41]. Dabrafenib showed antitumor activity with an overall intracranial response rate of 39 and $31 \%$ for the patients with BRAFV600E-mutant melanoma without and with prior brain irradiation, respectively. Median progression-free survival was 4 months, and median overall survival approximately 8 months in both cohorts. Objective responses were also seen in 5 of 33 patients ( $15 \%$ ) with BRAFV600K-mutant melanoma. In the safety analysis, only 1 patient developed treatment-related cerebral hemorrhage.

Although a preclinical study suggests that dabrafenib may have greater brain penetration compared with vemurafenib [48], there are no data comparing the clinical intracranial activity of dabrafenib and vemurafenib. Neoadjuvant studies in patients with resectable brain metastases are planned for dabrafenib (NCT01978236) and vemurafenib (NCT 01781026) which will provide information on brain penetration of these agents.

Trametinib is an orally available, small-molecule, selective inhibitor of MEK1 and MEK2 which was approved by US FDA in 2013 for the treatment of patients with unresectable or metastatic melanoma with BRAFV600E or V600K mutations. In a phase 3 open-labeled trial, 322 patients with metastatic melanoma with BRAFV600E or V600K mutation were randomized to receive either trametinib or chemotherapy (either dacarbazine or paclitaxel) in 2:1 ratio [20]. Median progression-free survival was improved to 4.8 months in the trametinib group compared to 1.5 months in the chemotherapy group. Overall survival rate at 6 months was $81 \%$ in the trametinib group and $67 \%$ in the chemotherapy group even though 51 of 108 patients ( $47 \%$ ) in the chemotherapy group crossed over to receive trametinib (hazard ratio for death, $0.54 ; 95 \% \mathrm{CI}, 0.32$ to $0.92 ; P=0.01$ ). The response rate was $22 \%$, and most common side effects were rash, diarrhea, and peripheral edema in the trametinib group. This trial included only a few patients with stable brain metastases ( 9 in trametinib and 2 in chemotherapy); therefore, the single-agent activity of trametinib against active melanoma brain metastases is currently not known.

Combination of dabrafenib and trametinib in BRAF inhibitor-na√Øve patients has shown improvement in response rate ( $76 \%$ vs. $54 \%$ ) as well as median progression survival ( 9.4 months vs. 5.8 months) compared with dabrafenib alone in a randomized phase II trial which led to accelerated approval of combination therapy by US FDA in 2014 [19]. Also, the incidence of cutaneous squamous cell carcinoma was $7 \%$ in combination group compared with $19 \%$ for dabrafenib monotherapy, suggesting that the addition of a MEK inhibitor was able to block the paradoxical activation of MAPK pathway that contributed to these skin lesions. The intracranial activity of this combination is going to be evaluated in a planned clinical trial (NCT02039947).

# 2.4 Combination 

### 2.4.1 Chemotherapy and Radiotherapy

Concurrent chemotherapy and WBRT have been evaluated in multiple clinical trials. In a phase III trial, the combination of fotemustine with whole-brain radiation delayed the time to CNS progression of melanoma brain metastases compared with fotemustine alone, but this benefit was not associated with a significant improvement in terms of objective disease control or overall survival [49]. The CytokineWorking Group conducted phase II trials of concurrent temozolomide and whole-brain radiation [43] as well as the concurrent temozolomide, thalidomide, and whole-brain radiation [4] for patients with brain metastases from melanoma which also showed very limited antitumor activity. Once again, the addition of thalidomide was associated with an unacceptably high rate of thromboembolic disease.

# 2.4.2 Immunotherapy and Radiotherapy 

Limited data are available investigating the use of definitive SRS and ipilimumab in patients with melanoma brain metastases. In a retrospective analysis of patients treated with radiosurgery, 27 of 77 patients received ipilimumab after radiosurgery [37]. Patients who received ipilimumab had a median survival of 21.3 months compared with 4.9 months in patients who did not receive this agent. However, these groups were not comparable. Although uni- and multivariable Cox proportional hazard analyses with data censored at 24 months demonstrated an improved hazard ratio (HR) for death in patients treated with ipilimumab compared to those who did not receive ipilimumab (HR 0.48 [95 \% CI, 0.24-0.93]; $P=0.03$ ), a significant role for ipilimumab could not be established in the final multivariate analysis (HR 0.61 [95 \% CI, 0.33-1.10]; $P=0.12$ ). Nonetheless, some groups have reported a sensitizing effect or even an abscopal effect for focused RT when used in conjunction with immunotherapy [54]. Consequently, the combination of ipilimumab and radiosurgery or whole-brain radiation is being prospectively investigated in clinical trials (NCT01703507).

### 2.4.3 BRAF Inhibitor and Radiotherapy

The efficacy of vemurafenib concomitant with or in patients who were previously treated with either SRS or whole-brain radiation was evaluated in a retrospective analysis in 12 patients with melanoma brain metastases [50]. Seven patients had a neurologic improvement, and radiographic responses were seen in 36 of 48 index lesions ( $75 \%$ ). This result suggests that BRAF inhibitor and radiotherapy-based techniques have high efficacy although they need to be validated in randomized controlled clinical trials. Of note, unusual skin reactions such as excessive acute radio-dermatitis and late skin reaction can occur during and after treatment with a combination of vemurafenib and whole-brain radiation [64]. Therefore, careful dermatologic monitoring is required for those who undergo concurrent radiation and BRAF inhibitor therapy. The safety and efficacy of dabrafenib combined with SRS are currently being investigated (NCT01721603).

## 3 Conclusion

The discovery of BRAFV600 mutation and the development of targeted therapies directed against this mutation as well as effective immunotherapies with durable benefits have revolutionized the treatment of patients with melanoma. Theapplication of stereotactic radiation therapy has provided an opportunity to control brain metastases in majority of patients with metastatic melanoma reducing the impact that these lesions have on mortality and enabling such patients to receive and potentially benefit from these novel systemic treatments. Encouragingly, several of these novel agents have shown antitumor activity against CNS metastases use approaches that are effective against extracranial disease. As a consequence, several effective treatment options are now available for patients with melanoma brain metastases. With these tools in hand, it is anticipated that further investigation into the optimal sequence and/or combination of systemic therapies and local therapies along with multidisciplinary team practice will continue to improve the outcome of patients with this previously life-limiting disease complication.

# References 

1. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, Rankin EM (2004) Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 22(11):2101-2107. doi:10.1200/jco.2004.11.044
2. Alessandretti M, Buzaid AC, Brandao R, Brandao EP (2013) Low-dose bevacizumab is effective in radiation-induced necrosis. Case Rep Oncol 6(3):598-601. doi:10.1159/ 000357401
3. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Curran WJ Jr (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363(9422):1665-1672. doi:10.1016/s0140-6736(04)16250-8
4. Atkins MB, Sosman JA, Agarwala S, Logan T, Clark JI, Ernstoff MS, Margolin KA (2008) Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer 113 (8):2139-2145. doi:10.1002/cncr. 23805
5. Ballo MT, Ross MI, Cormier JN, Myers JN, Lee JE, Gershenwald JE, Zagars GK (2006) Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys 64(1):106-113. doi:10.1016/j.ijrobp.2005.06.030
6. Bedikian AY, Wei C, Detry M, Kim KB, Papadopoulos NE, Hwu WJ, Hwu P (2011) Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma. Am J Clin Oncol 34(6):603-610. doi:10.1097/COC.0b013e3181f9456a
7. Bindal RK, Sawaya R, Leavens ME, Lee JJ (1993) Surgical treatment of multiple brain metastases. J Neurosurg 79(2):210-216. doi:10.3171/jns.1993.79.2.0210
8. Carlino MS, Atkins MB, Warneke CL et al (2010) Differences between Australia (OZ) and the United States (US) in the patterns, prognosis, and treatment of melanoma CNS metastases: Analysis from the PHAMOUS (prognostic heterogeneity in patients with advanced melanoma between OZ and the US) study. Paper presented at the Melanoma Congress
9. Chang EL, Selek U, III Hassenbusch SJ, Maor MH, Allen PK, Mahajan A, Woo SY (2005). Outcome variation among "radioresistant" brain metastases treated with stereotactic radiosurgery. Neurosurgery 56(5):936-945 (discussion 936-945)
10. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, McArthur GA (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507-2516. doi:10.1056/NEJMoa1103782
11. Chen G, Davies MA (2012) Emerging insights into the molecular biology of brain metastases. Biochem Pharmacol 83(3):305-31412. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949-954. doi:10.1038/nature00766
13. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Bedikian A (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117 (8):1687-1696. doi:10.1002/cncr. 25634
14. de la Monte SM, Moore GW, Hutchins GM (1983) Patterned distribution of metastases from malignant melanoma in humans. Cancer Res 43(7):3427-3433
15. Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, Rinderknecht JD (2014) Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 50(3):611-621. doi:10.1016/j.ejca.2013.11.002
16. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Kefford RF (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379(9829):1893-1901. doi:10.1016/s0140-6736(12) $60398-5$
17. Fertil B, Malaise EP (1985) Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys 11(9):1699-1707
18. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, Thompson JF (2004) Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22 (7):1293-1300. doi:10.1200/jco.2004.08.140
19. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Weber J (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367(18):1694-1703. doi:10.1056/NEJMoa1210093
20. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Schadendorf D (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367 (2):107-114. doi:10.1056/NEJMoa1203421

21. Gaspar LE, Mehta MP, Patchell RA, Burri SH, Robinson PD, Morris RE, Kalkanis SN (2010) The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96(1):17-32. doi:10.1007/s11060-009-0060-9
22. Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445(7130):851-857. doi:10.1038/nature05661
23. Guirguis LM, Yang JC, White DE, Steinberg SM, Liewehr DJ, Rosenberg SA, Schwartzentruber DJ (2002) Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother 25(1):82-87
24. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Ribas A (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369(2):134-144. doi:10.1056/NEJMoa1305133
25. Hauschild A, Grob JJ, Demidov LV et al (2013) An update on BREAK-3, a phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM)
26. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Chapman PB (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358-365. doi:10.1016/s0140-6736(12)60868-x
27. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (8):711-723. doi:10.1056/NEJMoa1003466
28. Hodi FS, Oble DA, Drappatz J, Velazquez EF, Ramaiya N, Ramakrishna N, Mihm M (2008) CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 5(9):557-561. doi:10.1038/ ncponc118329. Hong JJ, Rosenberg SA, Dudley ME, Yang JC, White DE, Butman JA, Sherry RM (2010) Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res 16(19):4892-4898. doi:10.1158/1078-0432.ccr-10-1507
30. Hurst R, White DE, Heiss J, Lee DS, Rosenberg SA, Schwartzentruber DJ (1999) Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: is craniotomy indicated? J Immunother 22(4):356-362
31. Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, Houghton AN (2005) Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 103(12):2590-2597. doi:10.1002/cncr. 21081
32. Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Avril MF et al (1990) Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66 (9): $1873-1878$
33. Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, Davies MA (2012) NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118(16):4014-4023. doi:10.1002/cncr. 26724
34. Jensen CA, Chan MD, McCoy TP, Bourland JD, deGuzman AF, Ellis TL, Tatter SB (2011) Cavity-directed radiosurgery as adjuvant therapy after resection of a brain metastasis. J Neurosurg 114(6):1585-1591. doi:10.3171/2010.11.jns10939
35. Johnson JD, Young B (1996) Demographics of brain metastasis. Neurosurg Clin N Am 7 (3):337-344
36. Kalkanis SN, Kondziolka D, Gaspar LE, Burri SH, Asher AL, Cobbs CS, Linskey ME (2010) The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96(1):33-43. doi:10.1007/s11060-009-0061-8
37. Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL (2012) Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 117(2):227-233. doi:10.3171/2012.5.jns111929
38. Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, Mueller RP (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29 (2):134-141. doi:10.1200/jco.2010.30.1655
39. Liew DN, Kano H, Kondziolka D, Mathieu D, Niranjan A, Flickinger JC, Lunsford LD (2011) Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg 114(3):769-779. doi:10.3171/2010.5.jns1014
40. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Kefford RF (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29(10):1239-1246. doi:10.1200/jco.2010.32.4327
41. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Schadendorf D (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13 (11):1087-1095. doi:10.1016/s1470-2045(12)70431-x
42. Lwu S, Goetz P, Monsalves E, Aryaee M, Ebinu J, Laperriere N, Zadeh G (2013) Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases. Oncol Rep 29(2):407-412. doi:10.3892/or. 2012.2139
43. Margolin K, Atkins B, Thompson A, Ernstoff S, Weber J, Flaherty L, Johnson D (2002) Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 128(4):214-218. doi:10.1007/ s00432-002-0323-8
44. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Hodi FS (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13(5):459-465. doi:10.1016/s1470-2045(12)70090-645. Mier JW, Vachino G, Klempner MS, Aronson FR, Noring R, Smith S, Atkins MB (1990) Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 76(10):1933-1940
46. Minniti G, Clarke E, Lanzetta G, Osti MF, Trasimeni G, Bozzao A, Enrici RM (2011) Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol 6:48. doi:10.1186/1748-717x-6-48
47. Mitchell MS (1989) Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J Clin Oncol 7(11):1701-1709
48. Mittapalli RK, Vaidhyanathan S, Dudek AZ, Elmquist WF (2013) Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther 344 (3):655-664. doi:10.1124/jpet.112.201475
49. Mornex F, Thomas L, Mohr P, Hauschild A, Delaunay MM, Lesimple T, Clavel M (2003) A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 13 (1):97-103. doi:10.1097/01.cmr.0000043161.28051.2d
50. Narayana A, Mathew M, Tam M, Kannan R, Madden KM, Golfinos JG, Pavlick AC (2013) Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 113(3):411416. doi:10.1007/s11060-013-1127-1
51. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Young B (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280(17):1485-1489
52. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Young B (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322(8):494-500. doi:10.1056/nejm199002223220802
53. Patel JK, Didolkar MS, Pickren JW, Moore RH (1978) Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 135(6):807-810
54. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Wolchok JD (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366 (10):925-931. doi:10.1056/NEJMoa1112824
55. Radbill AE1, Fiveash JF, Falkenberg ET, Guthrie BL, Young PE, Meleth S, Markert JM (2004) Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer 101(4):825-833
56. Ramakrishna N, Margolin KA (2013) Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases. Am Soc Clin Oncol Educ Book 33:399-403. doi:10.1200/EdBook_AM.2013.33.399
57. Robert C, Thomas L, Bondarenko I, O'Day S, Jeffrey Weber MD, Garbe C, Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517-2526. doi:10.1056/NEJMoa1104621
58. Rochet NM, Kottschade LA, Markovic SN (2011) Vemurafenib for melanoma metastases to the brain. N Engl J Med 365(25):2439-2441. doi:10.1056/NEJMc1111672
59. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Dudley ME (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17(13):4550-4557. doi:10.1158/10780432.ccr-11-0116
60. Samlowski WE, Watson GA, Wang M, Rao G, Klimo P Jr, Boucher K, Jensen RL (2007) Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer 109(9):1855-1862. doi:10.1002/cncr. 22605
61. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF (1998) Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88 (1):11-20. doi:10.3171/jns.1998.88.1.001162. Schartz NE, Farges C, Madelaine I, Bruzzoni H, Calvo F, Hoos A, Lebbe C (2010) Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res 20(3):247-250. doi:10.1097/CMR.0b013e3283364a37
63. Schouten LJ, Rutten J, Huveneers HA, Twijnstra A (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94(10):2698-2705
64. Schulze B, Meissner M, Wolter M, Rodel C, Weiss C (2014) Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports. Strahlenther Onkol 190(2):229-232. doi:10.1007/s00066-013-0474-3
65. Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG, Bottomley A (2013) A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol 31(1):65-72. doi:10.1200/jco.2011.41.0639
66. Soltys SG, Adler JR, Lipani JD, Jackson PS, Choi CY, Puataweepong P, Chang SD (2008) Stereotactic radiosurgery of the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys 70(1):187-193. doi:10.1016/j.ijrobp.2007.06.068
67. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Mehta M (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30(4):419-425. doi:10.1200/ jco.2011.38.0527
68. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Marais R (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366(3):207-215. doi:10.1056/NEJMoa1105358
69. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (26):2443-2454. doi:10.1056/NEJMoa1200690
70. Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH et al (1993) Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 33(6):583-590. doi:10.1002/ana. 410330605
71. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Marais R (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116(6):855-867
72. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Sznol M (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122-133. doi:10. 1056/NEJMoa1302369
73. Yu C, Chen JC, Apuzzo ML, O‚ÄôDay S, Giannotta SL, Weber JS, Petrovich Z (2002) Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys 52(5):1277-1287